At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 55 enrolled
Drug / intervention
Ferric Citratedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Transition to Ferric Citrate Among Hemodialysis and Peritoneal Dialysis Patients: A Phase 4 "Real World" Experience Study From Kaiser Permanente Southern California
In Brief
A Phase 4 clinical trial evaluating Ferric Citrate for Hyperphosphatemia. Completed, enrolled 55 participants across 1 site.
Detailed Summary
Transition to Ferric Citrate among Hemodialysis and Peritoneal Dialysis Patients: A Phase 4 "Real World" Experience Study from Kaiser Permanente Southern California
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHyperphosphatemia
CountriesUnited States
CollaboratorsKeryx Biopharmaceuticals
Timeline
Phase 4CompletedFinished
2017201820192020202120222023202420252026
First PostedMar 2017
Enrollment StartMay 2017
Primary CompletionSep 2019
TodayJul 2026
First PostedMar 15, 2017
Enrollment StartMay 1, 2017
Primary CompletionSep 14, 2019
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 9.3 years ago
Interventions
Ferric Citratedrug
One to two tablets of Ferric Citrate phosphorus binder administered by mouth before every meal to prevent dietary phosphorus absorption.